"This is promising, but it's not marketed anywhere in the world right now, and it hasn't been approved in any country," said Dr. Rachelle Doody, the study's principal investigator and Effie Marie Cain chair in Alzheimer's disease research at Baylor College of Medicine.
"This is coming along," she told ABC News. "It's coming along pretty quickly relative to other agents, but this drug and all the others are not cures for the disease."
Alzheimer's patients like Henes are optimistic.
"I can't wait. I am so excited about the possibility," Henes said. "If I can stay the way I am now until a drug that comes along, I will be a lucky person."
To learn more about participating in the Phase III clinical trials of Dimebon, visit this site, or call 1.877.888.6386.